On April 16, a research team led by Prof. Xin Ni from Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China, National Clinical Research Center for Respiratory Disease, and National Center for Pediatric Cancer Surveillance, published a groundbreaking study in The Lancet Child & Adolescent Health. The paper, titled "Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up", highlights the first-in-class RSV-specific antiviral drug, ziresovir. The study demonstrates that ziresovir significantly reduces viral load in infants and decreases the risk of long-term recurrent wheezing or asthma.

 

 

 

Fulltext link: https://pubmed.ncbi.nlm.nih.gov/40246359/

 

Cooperative Talent

 

 

Xin Ni

 

Chief Physician, Professor, and Doctoral Supervisor. Currently serves as: